CN107412334A - 复方控糖合剂及其制造方法 - Google Patents
复方控糖合剂及其制造方法 Download PDFInfo
- Publication number
- CN107412334A CN107412334A CN201710795775.6A CN201710795775A CN107412334A CN 107412334 A CN107412334 A CN 107412334A CN 201710795775 A CN201710795775 A CN 201710795775A CN 107412334 A CN107412334 A CN 107412334A
- Authority
- CN
- China
- Prior art keywords
- capsule
- compound
- mixture
- diabetes
- milligrams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- 239000002775 capsule Substances 0.000 claims description 56
- 229910000831 Steel Inorganic materials 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000010959 steel Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 4
- 238000005498 polishing Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 44
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 19
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 12
- 229930003779 Vitamin B12 Natural products 0.000 abstract description 7
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract description 7
- 235000019163 vitamin B12 Nutrition 0.000 abstract description 7
- 239000011715 vitamin B12 Substances 0.000 abstract description 7
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 abstract description 6
- 229930003427 Vitamin E Natural products 0.000 abstract description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 6
- 230000007246 mechanism Effects 0.000 abstract description 6
- 235000019165 vitamin E Nutrition 0.000 abstract description 6
- 229940046009 vitamin E Drugs 0.000 abstract description 6
- 239000011709 vitamin E Substances 0.000 abstract description 6
- 241000723347 Cinnamomum Species 0.000 abstract description 5
- 235000017803 cinnamon Nutrition 0.000 abstract description 5
- 239000011782 vitamin Substances 0.000 abstract description 5
- 239000000835 fiber Substances 0.000 abstract description 4
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 abstract description 4
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 3
- 229940046374 chromium picolinate Drugs 0.000 abstract description 3
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000395 magnesium oxide Substances 0.000 abstract description 3
- 230000010534 mechanism of action Effects 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 description 29
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
- 239000008280 blood Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 5
- 229910052720 vanadium Inorganic materials 0.000 description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000522254 Cassia Species 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000003130 cardiopathic effect Effects 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102000034573 Channels Human genes 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108091006300 SLC2A4 Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- QOWZHEWZFLTYQP-UHFFFAOYSA-K chromium(3+);triformate Chemical compound [Cr+3].[O-]C=O.[O-]C=O.[O-]C=O QOWZHEWZFLTYQP-UHFFFAOYSA-K 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 229920006300 shrink film Polymers 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种复方控糖合剂及其制造方法,所述复方控糖合剂包括组分及含量:食用可溶性纤维100‑2000毫克;维生素D3 200‑800国际单位;维生素E 30‑1500国际单位;吡啶甲酸铬30‑400毫克;硫酸氧钒15‑150毫克;肉桂粉100‑1000毫克;氧化镁30‑400毫克;维生素B12 10‑2000毫克。本发明根据糖尿病的作用机理的不同,通过大量实验,精心筛选出四类、八种营养物质作为“复方控糖合剂”,以便从不同分子水平控制或缓解胰岛素抵抗、糖耐受、和糖尿病。这种由四类不同作用机理、八种不同营养物质组成的“复方控糖合剂”通过对糖尿病发病机理不同分子水平靶点的精确控制,能最大程度地发挥不同成分对糖尿病治疗的协同作用,从而取得了有效的控制胰岛素抵抗、糖耐受和糖尿病的效果。
Description
技术领域
本发明属于糖尿病保健品或者药物领域,尤其是涉及一种能够有效控制糖尿病的复方控糖合剂及其制造方法。
背景技术
现有技术普遍认为二型糖尿病的发病机制源于因为年龄、肥胖、饮食、缺乏锻炼等原因造成肠道微生物失去平衡,有益肠道微生物相对减少,从而使肠道粘膜通透性增加,革兰氏阴性微生物脂多糖经肠道壁进入血液循环导致慢性炎症反应。免疫细胞释放淋巴因子IL-6,TNFa等,最终造成“胰岛素抵抗”和接下来的糖耐受和最终的糖尿病。尽管存在各种各样的抗糖尿病药物,但是,据估计,95%的糖尿病病人未能有效地将血糖控制在正常甚至是前期糖尿病水平。而长期的高血糖将不可避免地造成数年后的截肢、失明、肾功能衰竭和严重的心血管系统疾病。所以,目前国际上糖尿病控制的目标是提倡以药物、饮食、运动相结合的综合治疗方式。而多种营养素,如维生素和矿物质,已被发现对胰岛素抵抗、糖耐受、糖尿病有一定的治疗功效。
尽管一些科研文献报道各种维生素和矿物质对控制糖尿病有一定的功效,但是,由于普通百姓对科研成果知之甚少、营养品市场的管理相对混乱、更主要的是市场上几乎没有成熟的、经过科研考证的、特别设计用于糖尿病的控制控制的营养保健品。况且,即使每存在现成产品,要把它们购买齐全并坚持长期使用也是一件十分不切实际的事情。总之,尽管存在大量的科研成果,到目前为止,无论是中国还是国外尚没有一个复合营养品包含多种营养物质、着眼于不同的作用机理、针对不同靶分子用于控制胰岛素对抗、糖耐受和糖尿病的目的。
发明内容
本发明收集了针对四种不同的靶分子、八种经过系统科研证明对糖尿病有治疗功效的营养素,并制成复方合剂以达到控制或缓解胰岛素对抗、糖耐受和糖尿病的目的,填补了国内外的空缺,也必将成为糖尿病患者的福音。
为实现上述目的,本发明采用的技术方案为:
一种复方控糖合剂,包括组分及含量为:
进一步的,所述复方控糖合剂,包括组分及含量为:
进一步的,所述复方控糖合剂为复方合剂胶囊,片剂或者粉剂。
进一步的,所述复方合剂胶囊,制造方法包括步骤:
A):原料检验
称量各原料,并对原料的有效成分进行检测;
B):混合
将检测后的各组分进行混匀,制得混合物;
C):胶囊填充
用胶囊自动充填机,将胶囊内容物填充填入明胶硬胶囊中,装量为每粒0.3g。胶囊装在已消毒的不锈钢容器中,密闭。
进一步的:所述制造方法还包括步骤:
D):胶囊抛光
胶囊还可以进行抛光,用胶囊抛光分选机将胶囊抛光,并分选出不合格胶囊。合格胶囊装在已消毒的洁净不锈钢容器中,密闭。
本发明根据糖尿病的作用机理的不同,通过大量实验,精心筛选出四类、八种营养物质作为“复方控糖合剂”,以便从不同分子水平控制或缓解胰岛素抵抗、糖耐受、和糖尿病。这种由四类不同作用机理、八种不同营养物质组成的“复方控糖合剂”通过对糖尿病发病机理不同分子水平靶点的精确控制,能最大程度地发挥不同成分对糖尿病治疗的协同作用,从而取得了有效的控制胰岛素抵抗、糖耐受和糖尿病的效果。
附图说明
图1为糖尿病的发病原理和本发明的“复方控糖合剂”对糖尿病治疗的靶向分子示意图。
具体实施方式
下面结合附图和具体实施例对本发明作出进一步详细说明。
图1展示了糖尿病的发病原理和本发明的“复方控糖合剂”对糖尿病治疗的靶向分子。后者包括:1)作用于防止慢性炎、阻止胰岛素抵抗发生类营养素:可溶性食物纤维、维生素D、E;2)作用于促进或协同胰岛素功能类营养素:微量元素铬、钒;3)促进糖通道蛋白合成类营养素:肉桂皮粉;4)调节全身代谢功能以达到降糖效果类营养素:维生素B12、镁。这种由四类不同作用机理、八种不同营养物质组成的“复方控糖合剂”通过对糖尿病发病机理不同分子水平靶点的精确控制,能最大程度地发挥不同成分对糖尿病治疗的协同作用,最终达到有效的控制胰岛素抵抗、糖耐受和糖尿病的效果。
1)可溶性食物纤维。食物,包括蔬菜、水果、豆类、坚果等含有大量的可溶性食物纤维,对维护人体健康起着重要的作用。A、促进肠道益生菌的生长。可溶性食物纤维是肠道益生菌的粮食。特别是产丁酸盐类微生物对维持肠道壁粘膜的完 整性防止局部慢性炎症反应起着不可替代的作用。因此,可溶性纤维有间接防止细菌脂多糖进入血液循环、预防胰岛素对抗和糖尿病发生起着重要的作用。另外,微生物降解可溶性纤维后产生的短链脂肪酸还有维持身体的饱感作用,因而对减少过量进食造成的肥胖有一定的抑制作用。B、帮助维持血糖水平。食物可溶性纤维有减缓肠道对糖的吸收作用,从而降低对胰岛素的需求,降低糖尿病的发病率。C、降低血液胆固醇水平,降低高血压、糖尿病和心脏病的发病率。D、促进肠蠕动预防便秘,维持肠道正常生理功能。本复方制剂的可溶性食物纤维使用量是每剂100-2000毫克。
2)维生素D具有很强的抗微生物作用。可以以抵抗微生物脂多糖引起的慢性炎症反应,最终减轻或消除“胰岛素抵抗”。美国新英格兰医学中心一项研究对83,779个病人跟踪20年发现,每天补充800国际单位的维生素D能降低33%糖尿病发病率。多项研究显示,糖尿病病人普遍缺乏维生素D。所以,血液维生素D是糖尿病病人血相检查必不可少的项目之一。本复方制剂使用维生素D3剂量为200-800国际单位。
3)维生素E是一种强抗氧化剂。肥胖和糖尿病病人身体内往往缺乏抗氧化成分。研究证明维生素E能缓解胰岛素抗性和糖耐受。另一方面,糖尿病病人发生中风和心脏病的可能性比常人高出三倍,而研究表明,每天补充400国际单位的维生素E可以降低糖尿病病人因中风和心脏病死亡率的50%。本复方制剂使用维生素E剂量为20-1000毫克或30-1500国际单位.
4)吡啶甲酸铬:大量研究表明三价铬能有效地促进胰岛素与肌肉和脂肪细胞表面胰岛素受体的结合,促使糖顺利进入细胞,降低胰岛素抵抗和糖耐受。铬是常见的微量元素食品添加剂,无毒副作用。在消除糖尿病病源的同时,通过铬可快速消除胰岛素抵抗。本复方制剂使用吡啶甲酸铬30-400毫克。
5)硫酸氧钒:微量元素钒则有模拟胰岛素的作用,能减轻胰岛素抗性和糖耐受。其实,钒一直以来被用作药物治疗糖尿病,降低血糖,降低胆固醇和心脏病。钒还有抗微生物作用而被用于治疗结核和梅毒等感染性疾病。并用于运动员体能训练以提高成绩,还被用于预防癌症。所以,钒的抗微生物作用能阻止微生物脂多糖 引起的胰岛素抗性,而其类似胰岛素的功能进一步促进身体对糖的利用同时相对降低身体对胰岛素的需求,是糖尿病病人不可缺少的微量素。本复方合剂使用硫酸氧钒剂量为15-150毫克。
6)肉桂粉:有研究报道,由于长期的胰岛素抵抗,造成肌肉和脂肪细胞内糖通道蛋白GLUT4的表达严重降低。在此情况小,即使完全消除原病源、增加胰岛素分泌和增强胰岛素功能和胰岛素相对活性无法使糖分子快速进入细胞逆转胰岛素抵抗。美国研究显示中药肉桂对GLUT4表达的有很强的促进作用。因此,同时使用肉桂在进一步从不同的分子水平消除长期因胰岛素抵抗而带来的后遗症。肉桂是一味传统的中药,几乎没有副作用。本复方合计使用的肉桂皮粉为100-1000毫克。
7)氧化镁:微量元素镁更是身体不可缺少的成分。镁参加人体三百多个生物化学反应,主要参与能量代谢和蛋白质的合成。据美国一项研究报道,80%的美国人缺乏镁。研究表明镁离子能强化胰岛素的功能。而镁的缺乏往往也是造成糖尿病、高血压和心脏病的主要原因之一。而胰岛素耐受还能阻碍镁离子的运输,从而进一步加重胰岛素耐受。本复方合剂使用的氧化镁剂量为30-400毫克。
8)维生素B12是维持身体健康的神经系统和血液系统正常生理功能不可缺少的因素。维生素B12缺乏可造成神经损伤、神经病变和贫血。多项研究表明,糖尿病病人往往也存在维生素B12缺乏。另一方面,糖尿病最常用的药物二甲双胍能阻止食物中维生素B12的吸收,让身体已经存在的维生素B12缺乏更为严重。更为严重的是,长期高血糖造成的神经系统损害和病变完全相同。二者的叠加作用是糖尿病神经综合症出现更早更严重。所以,临床上维生素B12也是糖尿病病人血相检测的必查项目之一。本复方制剂使用维生素B12剂量为10-2000毫克。
实施例1
根据表1列出的八种营养素剂量将营养素制成单成分胶囊进行效果观察。使用人群为50-70岁,当前血糖控制效果不佳,血糖值在8-11之间的糖尿病患者。病人分为八组,每组16个病人,分别服用服用不同的营养素胶囊42天。服用前后分别检测并记录血糖数值。结果见表2。
单成分或者二联胶囊,以及全成分胶囊的制备方法,包括步骤:
A):原料检验
按照表1配方称量各原料,并对原料的有效成分进行检测;
B):混合
将检测后的各组分进行混匀(如单成分,本步骤则省略),制得混合物;
C):胶囊填充
用胶囊自动充填机,将胶囊内容物填充填入明胶硬胶囊(空心胶囊)中,装量为每粒0.3g。胶囊装在已消毒的不锈钢容器中,密闭,转下道工序。
D):胶囊抛光
胶囊还可以进行抛光,用胶囊抛光分选机将胶囊抛光,并分选出不合格胶囊。合格胶囊装在已消毒的洁净不锈钢容器中,密闭,转下道工序。
上述各组分的处理、配制胶囊内容物、胶囊充填、胶囊抛光、铝塑包装在10万级以上洁净区进行。
E)装袋:将合格的铝塑包装板,每5板为1组,装在防潮袋中,热合塑封,塑封温度为190-210℃。
小包装:每盒60粒(5板铝塑包装板):每盒内装1张产品说明书;小盒标识批号、生产日期、有效期;小盒外规定位置上贴防伪标签、封签。
中包装:每10盒为1组,用收缩膜进行热缩包装,塑封温度为190-210℃。
运输包装:每10中包装为1箱,大包装时上、下放垫板;每箱内放一张产品合格证,
箱外标识批号、生产日期、有效期;用胶带上下封口;用捆扎机扎2道打包带。
成品入库:包装结束后,成品入成品库。
本产品加工使用的饮用净水应符合CJ 94-2005的规定。所述步骤中的明胶硬胶囊(空心胶囊)应符合GB 13731的规定。
本领域技术人员,也可以按照现有技术制备片剂或者粉剂的工艺,将复方控糖合剂制成片剂或者粉剂,以供不同的消费者选择。
表1、复方控糖合剂营养素名称和剂量举例
表2、八种营养素的降血糖作用分析
病人服用营养素胶囊后血糖平均降低值为0.11-0.20(p<0.01),具有高度显著性统计学意义,p值在0.00001-0.0008之间。
实施例2
本专利申请所列营养素从功能上可分为四类:1)作用于防止慢性炎、阻止胰岛素抵抗发生;2)作用于促进或协同胰岛素功能类营养素;3)促进糖通道蛋白合成类营养素;4)调节全身代谢功能以达到降糖效果类营养素。为了进一步分析不 同功能营养素之间的协同作用,我们将营养素制成二联胶囊,其成分各代表四类营养素之一,分别为:肉桂粉+吡啶甲酸铬,肉桂粉+维生素D3,肉桂粉+维生素B12,硫酸氧钒+维生素E。
类似实施例1,我们选择的人群为50-70岁,当前血糖控制效果不佳,血糖值在8-11之间的糖尿病患者。病人被分为四组,每组16个病人,分别服用不同的营养素胶囊42天。服用前后分别检测并记录血糖数值。结果见表四。
病人服用二联营养素胶囊后血糖平均降低值为0.35-0.59(p<0.01),显著性地高于两种营养素单独作用之和,具有高度显著性统计学意义,p值都为0.00001。证明不同功能营养素之间存在协同作用。
表3、不同功能营养素间相互协同作用分析
实施例3
根据实施例1、表1中列出的八种营养素和相应的剂量,我们制成了含全部八种营养素的复方合剂胶囊并在人群中测试其降血糖效果。同样类似实施例1,人群为50-70岁,当前血糖控制效果不佳,血糖值在8-11之间的糖尿病患者共16人。每个病人服用复方营养素胶囊42天。服用前后分别检测并记录血糖数值。结果见表五。结果显示,复方合剂在用药前后血糖下降均值为1.91(p=0.00001),具有高度显著性统计学意义。结果进一步证明四类不同降血糖功能营养素的协同作用远远高于营养素单独使用的效果。
表4、八种营养素复方合剂的降血糖作用分析
以上内容是结合具体的优选实施方式对本发明所作的进一步详细说明,不能认定本发明的具体实施只局限于这些说明。对于本发明所属技术领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干简单推演或替换,都应当视为属于本发明的保护范围。
Claims (6)
1.一种复方控糖合剂,包括组分及含量为:
2.如权利要求1所述复方控糖合剂,其特征是:包括组分及含量为:
3.如权利要求1或者2所述复方控糖合剂,其特征是:所述复方控糖合剂为复方合剂胶囊。
4.如权利要求1或者2所述复方控糖合剂,其特征是:所述复方控糖合剂为复方合剂片剂或者粉剂。
5.如权利要求3所述的复方合剂胶囊,制造方法包括步骤:
A):原料检验
称量各原料,并对原料的有效成分进行检测;
B):混合
将检测后的各组分进行混匀,制得混合物;
C):胶囊填充
用胶囊自动充填机,将胶囊内容物填充填入明胶硬胶囊中,装量为每粒0.3g。胶囊装在已消毒的不锈钢容器中,密闭。
6.如权利要求5所述的复方合剂胶囊,其特征是:所述制造方法还包括包括步骤:
D):胶囊抛光
胶囊还可以进行抛光,用胶囊抛光分选机将胶囊抛光,并分选出不合格胶囊;合格胶囊装在已消毒的洁净不锈钢容器中,密闭。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710795775.6A CN107412334B (zh) | 2017-09-06 | 2017-09-06 | 复方控糖合剂及其制造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710795775.6A CN107412334B (zh) | 2017-09-06 | 2017-09-06 | 复方控糖合剂及其制造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107412334A true CN107412334A (zh) | 2017-12-01 |
CN107412334B CN107412334B (zh) | 2020-11-13 |
Family
ID=60432438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710795775.6A Active CN107412334B (zh) | 2017-09-06 | 2017-09-06 | 复方控糖合剂及其制造方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107412334B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1355169A (zh) * | 2000-11-28 | 2002-06-26 | 昆明贵金属研究所 | 钒化合物及其制备方法和用途 |
CN1435211A (zh) * | 2002-01-29 | 2003-08-13 | 陈神佑 | 复方蜗牛合剂的配方及其制备方法 |
CN1879753A (zh) * | 2006-05-16 | 2006-12-20 | 刘海涛 | 一种治疗肾脾两虚挟血瘀型糖尿病的药物 |
CN101229218A (zh) * | 2008-01-04 | 2008-07-30 | 深圳市普泰洛生物科技有限公司 | 用于治疗糖尿病的钒复方组合物及其制造方法 |
CN104107324A (zh) * | 2014-07-29 | 2014-10-22 | 上海中医药大学附属曙光医院 | 一种治疗2型糖尿病的中药复方制剂及其制备方法 |
CN106728580A (zh) * | 2017-01-10 | 2017-05-31 | 山东省内分泌与代谢病研究所 | 复方魔芋降血糖胶囊及其制备方法 |
-
2017
- 2017-09-06 CN CN201710795775.6A patent/CN107412334B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1355169A (zh) * | 2000-11-28 | 2002-06-26 | 昆明贵金属研究所 | 钒化合物及其制备方法和用途 |
CN1435211A (zh) * | 2002-01-29 | 2003-08-13 | 陈神佑 | 复方蜗牛合剂的配方及其制备方法 |
CN1879753A (zh) * | 2006-05-16 | 2006-12-20 | 刘海涛 | 一种治疗肾脾两虚挟血瘀型糖尿病的药物 |
CN101229218A (zh) * | 2008-01-04 | 2008-07-30 | 深圳市普泰洛生物科技有限公司 | 用于治疗糖尿病的钒复方组合物及其制造方法 |
CN104107324A (zh) * | 2014-07-29 | 2014-10-22 | 上海中医药大学附属曙光医院 | 一种治疗2型糖尿病的中药复方制剂及其制备方法 |
CN106728580A (zh) * | 2017-01-10 | 2017-05-31 | 山东省内分泌与代谢病研究所 | 复方魔芋降血糖胶囊及其制备方法 |
Non-Patent Citations (1)
Title |
---|
许曼音: "《糖尿病学》", 31 October 2003, 上海科学技术出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN107412334B (zh) | 2020-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Eliseeva et al. | Vitamin C (ascorbic acid)–description, benefits and where it is found | |
TW386877B (en) | Antitumour compositions containing taxane derivatives | |
US20160037811A1 (en) | Fruit and vegetable product for curing oral ulcer, and preparation method therefor | |
GB2529962A (en) | Multi-functional composition and preparation method and application thereof | |
CN101296693A (zh) | 持久力提高剂 | |
CN103656627A (zh) | 一种维c胶原蛋白复合泡腾片及其制备方法 | |
CN103599137B (zh) | 一种多种微量营养元素保健品 | |
CN104413527B (zh) | 复合功能饮料组合物 | |
CN105566451A (zh) | 一种促纤溶的土鳖小肽螯合物及其制备方法 | |
CN102847159A (zh) | 一种葡萄糖新陈代谢增强剂 | |
EP2891496A1 (en) | Pharmaceutical composition containing complex extract of aurantii nobilis pericarpium and crataegus as an active ingredient for treating or preventing obesity or lipid-related metabolic diseases | |
CN105410930A (zh) | 一种具有减肥瘦身、均衡营养功能的保健品及其制备方法 | |
DE69031694T3 (de) | Glutamin zur Behandlung von beeinträchtigten Abwehrkräften | |
CN108112992A (zh) | 一种功能医学营养减重配方及方法 | |
CN101982115A (zh) | 一种防治糖尿病慢性糖中毒的组合物 | |
CN107412334A (zh) | 复方控糖合剂及其制造方法 | |
CN106942728B (zh) | 一种苜蓿大麦制品及其制备方法和应用 | |
CN103168984A (zh) | 一种芦荟通便排毒的保健胶囊 | |
US20220323535A1 (en) | Health supplement | |
US11458150B2 (en) | Methylphosphinic acid compositions and methods for reducing aging | |
CN107260994A (zh) | 一种防治肿瘤的中药食疗组合物及其制备方法 | |
CN104225228B (zh) | 一种用于调节血糖的中药制剂 | |
CN114946954A (zh) | 一种含中药组分的益生菌复方组合物的固体饮料及制备方法 | |
CN101171037A (zh) | 营养补充剂透过粘膜吸收的可食用薄膜 | |
CN103948591B (zh) | 一种减肥药剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |